Judge Issues Stay in Merck’s 340B Contract Pharmacy Lawsuit

Merck
A federal district judge in Washington, D.C., put drug manufacturer Merck’s 340B contract pharmacy lawsuit against the federal government on hold pending a related federal appeals court decision.

A federal district judge in Washington, D.C., put drug manufacturer Merck’s 340B contract pharmacy lawsuit against the federal government on hold until after a federal circuit court in Washington rules in Novartis and United Therapeutics’ 340B contract pharmacy

Read More »

CMS Gets Conflicting Advice About Unwinding Drug Payment Cuts for 340B Hospitals

outpatient
Stakeholders offered CMS conflicting advice about how to reverse a nearly 30% cut in Medicare Part B drug reimbursement for hospitals’ 340B-purchased drugs since 2018. | Flickr.com/photos/rxb

340B stakeholders have offered federal healthcare officials conflicting advice about how best to respond to the U.S. Supreme Court’s June decision striking down a nearly 30% cut in Medicare Part B drug reimbursement for hospitals’ 340B-purchased drugs.

Read More »

Unichem Says 340B Audit Found it Overcharged Just Two Entities and Must Repay Them Just $110.20

Drug manufacturer Unichem said a HRSA 340B compliance audit found that it overcharged just two facilities and must repay them just $110.20.
Generic drug manufacturer Unichem says a 340B compliance audit found it overcharged just two entities and the repayment to both totals just $110.20.

Generic drug manufacturer Unichem says a 340B compliance audit found it overcharged only two entities and the repayment to both totals just $110.20.

Please Login or Become a Paid Subscriber to View this Content

Read More »

Judge Dismisses 340B Contract Pharmacy-Related Antitrust Claims Against Insulin Manufacturers

Federal District Court Rochester, N.Y.
A federal district judge in Rochester, N.Y., has dismissed two community health centers’ antitrust suit against insulin manufacturers over the companies’ 340B pricing policies.

A federal district judge has dismissed two community health centers’ federal and state antitrust claims against four insulin and diabetes drug manufacturers over the companies’ denials of 340B pricing when covered entities use contract pharmacies.

Read More »

Comments Due Today on How Feds Should Rectify Drug Payment Cuts for 340B Hospitals

September 2022
Today is the deadline for public comments on Medicare’s proposed rule for how it will pay for hospital outpatient services and clinician-administered drugs in 2023.

Today is the deadline for public comments on Medicare’s proposed rule for how it will pay for hospital outpatient services and clinician-administered drugs in 2023.

Please Login or Become a Paid Subscriber to View

Read More »

Restoring 340B Hospitals’ Part B Drug Payments Would Cut Net Outpatient Payments for 80% of Hospitals, Private Cancer Doctor-Funded Study Finds

Hospital, outpatient, Medicare, prescription drug
80% of hospitals in Medicare’s outpatient prospective payment system would see their net payments decline next year if CMS ends a nearly 30% cut in 340B hospitals’ drug payments, according to a private oncologist group funded study.

Eighty percent of all hospitals in Medicare’s outpatient prospective payment system—including 52% of all 340B hospitals—would see their net OPPS payments decline next year if Medicare ends a nearly 30% cut in 340B hospitals’ drug payments that began

Read More »

Judge Continues Stay in 340B Dispute Resolution Lawsuit

340B, Administrative dispute resolution, HHS
A federal district judge continued the stay in community health centers’ lawsuit over the 340B administrative dispute resolution process.

A federal district judge on Wednesday continued the stay in community health centers’ lawsuit against federal health officials over the administrative dispute resolution process for the 340B program after accepting the explanation for a missed deadline to file

Read More »

Federal Judge Asks About Overdue Status Report in 340B Dispute Resolution Case

Florence Pan
U.S. District Judge Florence Pan signaled her displeasure with NACHC and the federal government for missing a Sept. 3 deadline for a legal filing.

A federal district judge in Washington, D.C., yesterday ordered community health centers to answer why she should not dismiss their lawsuit against federal health officials over the administrative dispute resolution process for the 340B program.

Read More »

MedPAC May Back a Cut in Part B Drug Payments, This Time Not for 340B Hospitals Only

MedPAC
MedPAC is considering whether to recommend reducing the 6% add-on to Part B drug reimbursement to decrease the incentives for providers to use higher-priced drugs.

Congressional Medicare advisers are weighing whether to recommend converting the 6% add-on to Part B drug reimbursement to a fixed fee capped at $175 for drugs that cost $15,000 or more, phased in starting with drugs costing above

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report